

HCV

*D*rug

*R*esistance

*A*dvisory

*G*roup

HCV DRAG: History

- Outgrowth of proposal at the 1st International Workshop on Hepatitis C: Resistance and New Compounds (October, 2006)
- *Ad hoc* group approached the Forum for Collaborative HIV Research for organizational support

HCV DRAG: Structure

- Participants
 - Scientists responsible for HCV genotypic and phenotypic clinical virology studies required for the conduct of clinical trials
 - Scientists from academia and industry
- Advisors
 - Experts in HIV and HBV resistance studies
- Organizing Committee
 - Ann Kwong, Charles Boucher, Chip Schooley, Dale Kempf, Jules O'Rear, Neil Parkin, Nick Cammack
 - Ben Cheng, Veronica Miller

HCV DRAG: Purpose

- Bring together parties interested in and working in HCV drug resistance to discuss issues pertinent to HCV drug/biologic development and resistance testing

HCV DRAG: Goals

- Produce consensus recommendations of appropriate methodology for HCV resistance testing
 - For drug/biologic development
 - For clinical practice
- Provide scientific guidance to facilitate discussion between industry and regulatory agencies in areas of HCV drug resistance

HCV DRAG: Measurables

- Presentations/abstracts
 - AASLD, EASL
 - HCV Resistance Workshops
- White papers/manuscripts
 - Consensus guidelines

HCV DRAG: Today's Goals

- Identify the questions:
 - Genotype
 - Phenotype
 - Clinical
- Form working groups
- Define timetables for action items

HCV DRAG: Today's Agenda

HBV/HIV lessons learned

Scott Bowden, Doug Richman

Regulatory perspective

Jules O'Rear

Genotype

Ann Kwong

Clinical

Chip Schooley

Phenotype

Neil Parkin

Group discussion/next steps/timelines

Group